Total Payments
$7,343
2024 Payments
$1,522
Companies
26
Transactions
266
Medicare Patients
2,205
Medicare Billing
$184,349
Payment Breakdown by Category
Food & Beverage$5,448 (74.2%)
Travel$1,895 (25.8%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $5,448 | 261 | 74.2% |
| Travel and Lodging | $1,895 | 5 | 25.8% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $1,522 | 81 | $0 (2024) |
| Gilead Sciences, Inc. | $1,447 | 89 | $0 (2024) |
| Covidien LP | $1,320 | 6 | $0 (2018) |
| Boston Scientific Corporation | $1,203 | 11 | $0 (2023) |
| Takeda Pharmaceuticals U.S.A., Inc. | $292.24 | 15 | $0 (2024) |
| PFIZER INC. | $275.38 | 18 | $0 (2024) |
| Celgene Corporation | $198.94 | 10 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $162.95 | 5 | $0 (2024) |
| Intercept Pharmaceuticals, Inc. | $120.95 | 5 | $0 (2024) |
| GENZYME CORPORATION | $118.08 | 4 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,522 | 75 | Gilead Sciences, Inc. ($472.46) |
| 2023 | $1,222 | 55 | Gilead Sciences, Inc. ($293.31) |
| 2022 | $455.37 | 17 | ABBVIE INC. ($236.24) |
| 2021 | $683.89 | 38 | AbbVie Inc. ($422.15) |
| 2020 | $504.55 | 35 | AbbVie Inc. ($215.35) |
| 2019 | $540.79 | 26 | Gilead Sciences, Inc. ($268.63) |
| 2018 | $1,046 | 13 | Boston Scientific Corporation ($972.79) |
| 2017 | $1,368 | 7 | Covidien LP ($1,300) |
All Payment Transactions
266 individual payment records from CMS Open Payments — Page 1 of 11
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/11/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $25.83 | General |
| Category: IMMUNOLOGY | ||||||
| 12/10/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $15.93 | General |
| Category: Immunology | ||||||
| 12/10/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $6.72 | General |
| 12/07/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $33.54 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/03/2024 | Mirum Pharmaceuticals, Inc. | Livmarli (Drug) | Food and Beverage | In-kind items and services | $33.02 | General |
| Category: Alagille syndrome | ||||||
| 11/21/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $25.03 | General |
| 11/19/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $6.55 | General |
| 11/13/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $24.54 | General |
| Category: IMMUNOLOGY | ||||||
| 11/13/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $4.47 | General |
| 11/07/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $6.14 | General |
| 10/29/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $5.92 | General |
| 10/25/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $22.14 | General |
| 10/23/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $30.77 | General |
| 10/23/2024 | ABBVIE INC. | SKYRIZI (Biological), RINVOQ | Food and Beverage | In-kind items and services | $22.98 | General |
| Category: IMMUNOLOGY | ||||||
| 10/18/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $32.40 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 10/15/2024 | Takeda Pharmaceuticals U.S.A., Inc. | GATTEX (Drug) | Food and Beverage | In-kind items and services | $8.38 | General |
| Category: INTERNAL MEDICINE | ||||||
| 10/15/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $6.75 | General |
| 10/10/2024 | Ipsen Biopharmaceuticals, Inc | IQIRVO (Drug) | Food and Beverage | In-kind items and services | $33.25 | General |
| Category: Rare Disease | ||||||
| 10/10/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $6.54 | General |
| 10/09/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $27.77 | General |
| Category: IMMUNOLOGY | ||||||
| 10/08/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $28.00 | General |
| 10/01/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $12.82 | General |
| 09/28/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $33.75 | General |
| Category: LIVER DISEASE | ||||||
| 09/24/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $7.67 | General |
| 09/18/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $21.89 | General |
| Category: Neuroscience | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 487 | 586 | $197,475 | $43,533 |
| 2022 | 12 | 584 | 689 | $236,659 | $50,270 |
| 2021 | 11 | 564 | 674 | $165,828 | $49,241 |
| 2020 | 14 | 570 | 652 | $142,091 | $41,306 |
Total Patients
2,205
Total Services
2,601
Medicare Billing
$184,349
Procedure Codes
60
All Medicare Procedures & Services
60 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 48 | 48 | $37,152 | $9,609 | 25.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 47 | 86 | $21,414 | $5,984 | 27.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 42 | 72 | $17,928 | $5,109 | 28.5% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 58 | 59 | $40,828 | $4,361 | 10.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 75 | 88 | $14,872 | $4,224 | 28.4% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 51 | 52 | $27,196 | $3,690 | 13.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 58 | 73 | $12,337 | $3,599 | 29.2% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Facility | 2023 | 44 | 44 | $9,240 | $2,613 | 28.3% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 13 | 13 | $4,394 | $1,387 | 31.6% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 25 | 25 | $5,250 | $1,094 | 20.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 12 | 12 | $4,092 | $952.29 | 23.3% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 14 | 14 | $2,772 | $910.14 | 32.8% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2022 | 56 | 57 | $44,118 | $11,520 | 26.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 76 | 100 | $16,900 | $4,742 | 28.1% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2022 | 72 | 72 | $49,824 | $4,718 | 9.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 43 | 70 | $17,430 | $4,557 | 26.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 37 | 61 | $15,189 | $4,377 | 28.8% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 58 | 58 | $30,334 | $4,129 | 13.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 52 | 72 | $12,168 | $3,388 | 27.8% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 27 | 27 | $9,126 | $2,699 | 29.6% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Facility | 2022 | 32 | 32 | $6,720 | $2,030 | 30.2% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 26 | 30 | $5,370 | $1,775 | 33.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 19 | 19 | $6,479 | $1,697 | 26.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 17 | 17 | $5,797 | $1,513 | 26.1% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 27 | 27 | $5,670 | $1,299 | 22.9% |
About Dr. Christopher Aoki, M.D
Dr. Christopher Aoki, M.D is a Gastroenterology healthcare provider based in Sacramento, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/02/2006. The National Provider Identifier (NPI) number assigned to this provider is 1164460499.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Christopher Aoki, M.D has received a total of $7,343 in payments from pharmaceutical and medical device companies, with $1,522 received in 2024. These payments were reported across 266 transactions from 26 companies. The most common payment nature is "Food and Beverage" ($5,448).
As a Medicare-enrolled provider, Aoki has provided services to 2,205 Medicare beneficiaries, totaling 2,601 services with total Medicare billing of $184,349. Data is available for 4 years (2020–2023), covering 60 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Other Specialties Gastroenterology
- Location Sacramento, CA
- Active Since 06/02/2006
- Last Updated 11/19/2008
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1164460499
Products in Payments
- Beacon (Device) $1,300
- GENERAL BILIARY DEVICES (Device) $848.65
- HUMIRA (Biological) $638.25
- RINVOQ (Biological) $482.52
- DUPIXENT (Biological) $281.03
- SKYRIZI (Biological) $221.46
- ENTYVIO (Biological) $215.20
- ZEPOSIA (Drug) $198.94
- XELJANZ (Drug) $198.06
- Resolution Clip (Device) $176.28
- OCALIVA (Drug) $120.95
- NA (Device) $104.12
- Olympus EUS Devices (Device) $101.33
- ACQUIRE (Device) $101.25
- TERLIVAZ (Drug) $86.66
- INFLECTRA (Biological) $77.32
- IMFINZI (Biological) $65.94
- Livmarli (Drug) $63.73
- OTHER- BSC PRODUCT NOT LISTED (Device) $53.85
- MAVYRET (Drug) $50.05
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in Sacramento
Dr. Joseph Leung, M.d, M.D
Gastroenterology — Payments: $382,939
Gastroenterology $382,939
Christopher Bowlus, M.d, M.D
Gastroenterology — Payments: $174,596
Gastroenterology $174,596
Dr. Antonio Mendoza Ladd, M.d, M.D
Gastroenterology — Payments: $84,349
Gastroenterology $84,349
Dr. Kuldeep Tagore, M.d, M.D
Gastroenterology — Payments: $53,535
Gastroenterology $53,535
Abdul Khaleq, Md, MD
Gastroenterology — Payments: $48,069
Gastroenterology $48,069
Dr. Valentina Medici, M.d, M.D
Gastroenterology — Payments: $30,237
Gastroenterology $30,237